My Bibliography

select

Uriepero-Palma A, Márquez ME, Payque E, Mediavilla-Varela M, Gamal W, Maharaj K, Powers J, Chavez J, Eksioglu E, Sernbo S, Palacios F, Querol-Rivas J, Ortega C, Uria R, Santos GD, Oliver C, Landoni AI, Sahakian E, Oppezzo P, Pinilla-Ibarz J. Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL. Blood Adv. 2025 Oct 28;9(20):5219-5233. doi: 10.1182/bloodadvances.2025016061. Review. PubMed PMID: 40720748; PubMed Central PMCID: PMC12550715.

select

Gamal W, Goedhart NB, Simon-Molas H, Mediavilla-Varela M, Uriepero-Palma A, Peters FS, Maharaj K, Chavez JC, Powers J, Obermayer A, Shaw TI, Conejo-Garcia JR, Rodriguez PC, Sahakian E, Pinilla-Ibarz J, Kater AP. Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model. Blood Adv. 2025 May 27;9(10):2511-2529. doi: 10.1182/bloodadvances.2024014822. PubMed PMID: 39938006; PubMed Central PMCID: PMC12148389.

select

Tebbi CK, Yan J, Sahakian E, Mediavilla-Varela M, Pinilla-Ibarz J, Patel S, Rottinghaus GE, Liu RY, Dennison C. Mycovirus-Containing Aspergillus flavus Alters Transcription Factors in Normal and Acute Lymphoblastic Leukemia Cells. Int J Mol Sci. 2024 Sep 26;25(19). doi: 10.3390/ijms251910361. PubMed PMID: 39408690; PubMed Central PMCID: PMC11476453.

select

Gamal W, Mediavilla-Varela M, Uriepero-Palma A, Pinilla-Ibarz J, Sahakian E. Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia. Int J Mol Sci. 2024 Jun 7;25(12). doi: 10.3390/ijms25126324. PubMed PMID: 38928031; PubMed Central PMCID: PMC11203624.

select

Tebbi CK, Sahakian E. Comment on "Association between Residential Proximity to Viticultural Areas and Childhood Acute Leukemia Risk in Mainland France: GEOCAP Case-Control Study, 2006-2013". Environ Health Perspect. 2024 Apr;132(4):48003. doi: 10.1289/EHP14904. Epub 2024 Apr 24. PubMed PMID: 38656821; PubMed Central PMCID: PMC11042526.

select

Chavez JC, Grajales A, Sandoval-Sus J, Turba E, Nodzon L, Uriepero-Palma A, Ammad-Ud-Din M, Sahakian E, Komrokji R, Sokol L, Locke FL, Shah B, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Bello C, Pinilla-Ibarz J. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis. Clin Lymphoma Myeloma Leuk. 2024 Jun;24(6):382-391.e2. doi: 10.1016/j.clml.2024.02.001. Epub 2024 Feb 13. PubMed PMID: 38508880.

select

Gamal W, Sahakian E, Pinilla-Ibarz J. The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?. Blood Adv. 2023 Jun 13;7(11):2401-2417. doi: 10.1182/bloodadvances.2022008985. Review. PubMed PMID: 36574293; PubMed Central PMCID: PMC10238851.

select

Maharaj K, Uriepero A, Sahakian E, Pinilla-Ibarz J. Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies. Front Immunol. 2022;13:943354. doi: 10.3389/fimmu.2022.943354. eCollection 2022. Review. PubMed PMID: 35979372; PubMed Central PMCID: PMC9376239.

select

Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, Sudalagunta P, Canevarolo RR, Siqueira Silva MDC, Alugubelli RR, Dai HA, Kulkarni A, Dalton WS, Hampton OA, Welsh EA, Teer JK, Tungesvik A, Wright KL, Pinilla-Ibarz J, Sotomayor EM, Shain KH, Brayer J. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021 Dec 22;6(24). doi: 10.1172/jci.insight.151713. PubMed PMID: 34793338; PubMed Central PMCID: PMC8783683.

select

Perez L, Fernandez H, Kharfan-Dabaja M, Khimani F, Betts B, Mishra A, Ayala E, Locke FL, Ochoa-Bayona L, Nieder M, Pidala J, Achille A, Powers J, Sahakian E, Thapa R, Wang X, Anasetti C. A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Adv. 2021 Jul 13;5(13):2740-2750. doi: 10.1182/bloodadvances.2021004225. PubMed PMID: 34242388; PubMed Central PMCID: PMC8288668.

select

Chen J, Cheng F, Sahakian E, Powers J, Wang Z, Tao J, Seto E, Pinilla-Ibarz J, Sotomayor EM. HDAC11 regulates expression of C/EBPβ and immunosuppressive molecules in myeloid-derived suppressor cells. J Leukoc Biol. 2021 May;109(5):891-900. doi: 10.1002/JLB.1A1119-606RRR. Epub 2021 Apr 18. PubMed PMID: 33866588.

select

Tebbi CK, Badiga A, Sahakian E, Powers JJ, Achille AN, Patel S, Migone F. Exposure to a mycovirus containing Aspergillus Flavus reproduces acute lymphoblastic leukemia cell surface and genetic markers in cells from patients in remission and not controls. Cancer Treat Res Commun. 2021;26:100279. doi: 10.1016/j.ctarc.2020.100279. Epub 2020 Dec 11. PubMed PMID: 33348275.

select

Maharaj K, Powers JJ, Mediavilla-Varela M, Achille A, Gamal W, Quayle S, Jones SS, Sahakian E, Pinilla-Ibarz J. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model. Front Immunol. 2020;11:590072. doi: 10.3389/fimmu.2020.590072. eCollection 2020. PubMed PMID: 33329575; PubMed Central PMCID: PMC7719839.

select

Maharaj K, Powers JJ, Achille A, Mediavilla-Varela M, Gamal W, Burger KL, Fonseca R, Jiang K, Miskin HP, Maryanski D, Monastyrskyi A, Duckett DR, Roush WR, Cleveland JL, Sahakian E, Pinilla-Ibarz J. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020 Jul 14;4(13):3072-3084. doi: 10.1182/bloodadvances.2020001800. PubMed PMID: 32634240; PubMed Central PMCID: PMC7362385.

select

Tebbi CK, Badiga A, Sahakian E, Arora AI, Nair S, Powers JJ, Achille AN, Jaglal MV, Patel S, Migone F. Plasma of Acute Lymphoblastic Leukemia Patients React to the Culture of a Mycovirus Containing Aspergillus flavus. J Pediatr Hematol Oncol. 2020 Jul;42(5):350-358. doi: 10.1097/MPH.0000000000001845. PubMed PMID: 32576782.

select

Yue L, Sharma V, Horvat NP, Akuffo AA, Beatty MS, Murdun C, Colin C, Billington JMR, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville LN, Pinilla-Ibarz J, Reuther GW, Wright KL, Conti C, Lee JY, Zheng X, Ng PY, Martin MW, Marshall CG, Koomen JM, Levine RL, Verma A, Grimes HL, Sotomayor EM, Shao Z, Epling-Burnette PK. HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood. 2020 Jan 16;135(3):191-207. doi: 10.1182/blood.2019895326. PubMed PMID: 31750881; PubMed Central PMCID: PMC6966930.

select

Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, Kim J, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee NH, Kozikowski A, Villagra A. Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep. 2019 Oct 10;9(1):14824. doi: 10.1038/s41598-019-51403-6. PubMed PMID: 31597938; PubMed Central PMCID: PMC6785545.

select

Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, Kim J, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee NH, Kozikowski A, Villagra A. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep. 2019 Apr 16;9(1):6136. doi: 10.1038/s41598-019-42237-3. PubMed PMID: 30992475; PubMed Central PMCID: PMC6467894.

select

Maharaj K, Powers JJ, Achille A, Deng S, Fonseca R, Pabon-Saldana M, Quayle SN, Jones SS, Villagra A, Sotomayor EM, Sahakian E, Pinilla-Ibarz J. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Adv. 2018 Nov 13;2(21):3012-3024. doi: 10.1182/bloodadvances.2018020065. PubMed PMID: 30425065; PubMed Central PMCID: PMC6234358.

select

Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leuk Res. 2018 Nov;74:89-96. doi: 10.1016/j.leukres.2018.10.002. Epub 2018 Oct 9. PubMed PMID: 30340199; PubMed Central PMCID: PMC7787269.

select

Perez L, Fernandez H, Horna P, Riches M, Locke F, Field T, Powers J, Sahakian E, Villagra A, Mishra A, Betts B, Kharfan-Dabaja M, Beato F, Ochoa-Bayona L, Pidala J, Anasetti C. Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. Bone Marrow Transplant. 2018 Nov;53(11):1434-1444. doi: 10.1038/s41409-018-0163-z. Epub 2018 Apr 18. PubMed PMID: 29670210; PubMed Central PMCID: PMC7771280.

select

Maharaj K, Sahakian E, Pinilla-Ibarz J. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia. Blood Adv. 2017 Sep 26;1(21):1867-1875. doi: 10.1182/bloodadvances.2017006809. eCollection 2017 Sep 26. Review. PubMed PMID: 29296833; PubMed Central PMCID: PMC5728096.

select

Sahakian E, Chen J, Powers JJ, Chen X, Maharaj K, Deng SL, Achille AN, Lienlaf M, Wang HW, Cheng F, Sodré AL, Distler A, Xing L, Perez-Villarroel P, Wei S, Villagra A, Seto E, Sotomayor EM, Horna P, Pinilla-Ibarz J. Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology. J Leukoc Biol. 2017 Aug;102(2):475-486. doi: 10.1189/jlb.1A0415-176RRR. Epub 2017 May 26. PubMed PMID: 28550123; PubMed Central PMCID: PMC6608079.

select

Chen J, Sahakian E, Powers J, Lienlaf M, Perez-Villarroel P, Knox T, Villagra A. Functional Analysis of Histone Deacetylase 11 (HDAC11). Methods Mol Biol. 2016;1436:147-65. doi: 10.1007/978-1-4939-3667-0_11. PubMed PMID: 27246214; PubMed Central PMCID: PMC7882396.

select

Powers J, Lienlaf M, Perez-Villarroel P, Deng S, Knox T, Villagra A, Sahakian E. Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies. Methods Mol Biol. 2016;1436:129-45. doi: 10.1007/978-1-4939-3667-0_10. PubMed PMID: 27246213.

select

Chen J, Sahakian E, Powers J, Lienlaf M, Perez-Villarroel P, Knox T, Villagra A. Erratum to: Functional Analysis of Histone Deacetylase 11 (HDAC11). Methods Mol Biol. 2016;1436:E1. doi: 10.1007/978-1-4939-3667-0_22. PubMed PMID: 27535557.

select

Sahakian E, Powers JJ, Chen J, Deng SL, Cheng F, Distler A, Woods DM, Rock-Klotz J, Sodre AL, Youn JI, Woan KV, Villagra A, Gabrilovich D, Sotomayor EM, Pinilla-Ibarz J. Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol Immunol. 2015 Feb;63(2):579-85. doi: 10.1016/j.molimm.2014.08.002. Epub 2014 Aug 23. PubMed PMID: 25155994; PubMed Central PMCID: PMC4252813.

select

Cheng F, Lienlaf M, Wang HW, Perez-Villarroel P, Lee C, Woan K, Rock-Klotz J, Sahakian E, Woods D, Pinilla-Ibarz J, Kalin J, Tao J, Hancock W, Kozikowski A, Seto E, Villagra A, Sotomayor EM. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. J Immunol. 2014 Sep 15;193(6):2850-62. doi: 10.4049/jimmunol.1302778. Epub 2014 Aug 8. PubMed PMID: 25108026; PubMed Central PMCID: PMC4157123.

select

Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid. 2013;8:37-45. doi: 10.2147/CE.S34068. Epub 2013 May 16. PubMed PMID: 23717217; PubMed Central PMCID: PMC3662532.

select

Cheng F, Wang H, Horna P, Wang Z, Shah B, Sahakian E, Woan KV, Villagra A, Pinilla-Ibarz J, Sebti S, Smith M, Tao J, Sotomayor EM. Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Res. 2012 Sep 1;72(17):4440-8. doi: 10.1158/0008-5472.CAN-11-3619. Epub 2012 Jun 22. PubMed PMID: 22728650; PubMed Central PMCID: PMC3990429.

select

Woan KV, Sahakian E, Sotomayor EM, Seto E, Villagra A. Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol. 2012 Jan;90(1):55-65. doi: 10.1038/icb.2011.96. Epub 2011 Nov 22. Review. PubMed PMID: 22105512; PubMed Central PMCID: PMC3990411.

select

Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, Seto E, Bhalla K, Villagra A, Sotomayor EM. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol. 2011 Apr 1;186(7):3986-96. doi: 10.4049/jimmunol.1001101. Epub 2011 Mar 2. PubMed PMID: 21368229; PubMed Central PMCID: PMC3998678.

select

Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010 Sep 15;16(18):4583-94. doi: 10.1158/1078-0432.CCR-10-0733. Epub 2010 Aug 11. PubMed PMID: 20702612; PubMed Central PMCID: PMC3874864.

select

Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S, Djeu JY. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther. 2010 Jun;9(6):1831-41. doi: 10.1158/1535-7163.MCT-09-0880. Epub 2010 May 25. PubMed PMID: 20501799; PubMed Central PMCID: PMC3874868.

select

Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall NR, Lilly MB, De Leon M, Casiano CA. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer. 2009 Aug 28;8:68. doi: 10.1186/1476-4598-8-68. PubMed PMID: 19715609; PubMed Central PMCID: PMC2741463.

select

Parrish YK, Baez I, Milford TA, Benitez A, Galloway N, Rogerio JW, Sahakian E, Kagoda M, Huang G, Hao QL, Sevilla Y, Barsky LW, Zielinska E, Price MA, Wall NR, Dovat S, Payne KJ. IL-7 Dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow. J Immunol. 2009 Apr 1;182(7):4255-66. doi: 10.4049/jimmunol.0800489. PubMed PMID: 19299724; PubMed Central PMCID: PMC2659466.

select

Zemskova M, Sahakian E, Bashkirova S, Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem. 2008 Jul 25;283(30):20635-44. doi: 10.1074/jbc.M709479200. Epub 2008 Apr 21. PubMed PMID: 18426800; PubMed Central PMCID: PMC3258959.

select

Payne KJ, Huang G, Sahakian E, Zhu JY, Barteneva NS, Barsky LW, Payne MA, Crooks GM. Ikaros isoform x is selectively expressed in myeloid differentiation. J Immunol. 2003 Mar 15;170(6):3091-8. doi: 10.4049/jimmunol.170.6.3091. PubMed PMID: 12626565.